"Stemtech's Annual Incentive Cruise Sets Sail With Top Earners on Board; Colombia Pre-Registration Now Open and Product Expansion Unveiled for Ecuador"

Before the REORGANIZATION, Stemtech thrived IN COLOMBIA, generating $10 million and boasting 3,000 IBPs in the Colombian market.

NAPLES, FL / ACCESSWIRE / December 12, 2023 / STEMTECH CORPORATION (OTCQB:STEK) Stemtech, the pioneer in all-natural, plant-based stem cell nutrition wellness solutions, announces a significant step in its global expansion strategy with the re-entry into the Colombian market and the planned expansion of its product line in Ecuador. These strategic moves are poised to unlock new opportunities and consolidate Stemtech's position as a key player in the wellness industry, setting the stage for robust growth in 2024.

Re-Entry into the Colombian Market

Prior to the recent reorganization of the company, Colombia stood as a robust market for Stemtech, with its products enjoying strong brand recognition and a dedicated user base, particularly for its flagship product, Stemrelease3™. Before the reorganization of the Colombian market, Stemtech was thriving, generating over $10 million in revenue and boasting over 3 thousand Independent Business Partners (IBPs).

Exciting Pre-Registration Opportunity for Independent Business Partners (IBP)s:

In tandem with the Colombian market re-entry, Stemtech is thrilled to extend a special invitation to Independent Business Partners (IBPs) to pre-register, providing motivated individuals with an opportunity to generate income for their families and enhance their overall well-being. Be among the first to access these groundbreaking solutions by pre-registering at Stemtech's Colombia Pre-Registration section on the stemtech.com website. Secure your spot and become a part of the wellness revolution sweeping across Colombia. We will also be adding this feature for our existing Ecuador market.

Stemtech's Planned Product Line Expansion in Ecuador will feature StemFlo Advanced® Circulation support and MigraStem™ migration enhancer. This will provide the full Release, Circulate, Migrate (RCM System) for our Ecuador business.

Self-Sustained Growth Model:

Importantly, Stemtech is aligned to expand markets and grow revenue with its current structure, eliminating the need for additional corporate resources. This self-sustained growth model exemplifies the company's strategic efficiency, allowing it to capitalize on emerging opportunities without additional strain on corporate infrastructure.

Celebrating Top Producers:

In tandem with its strategic market moves, Stemtech is excited to kick off its end-of-year Cruise for its top producers. Stemtech is thrilled to be sailing the South Caribbean on the Royal Caribbean Rhapsody of the Seas, which began on Saturday, December 9^th through the 16^th with its top global leaders who earned the opportunity by qualifying for an incentive contest which began in June 2023. Stemtech looks forward to seeing this number continue to grow substantially in the coming years as more IBPs strive for excellence and qualify for this exceptional reward. Qualification for the cruise is a testament to the dedication and outstanding performance of IBPs, emphasizing Stemtech's commitment to recognizing and rewarding excellence within its community.

Qualifying IBPs showcase exceptional dedication and achievement within the Stemtech community, and the cruise serves as a symbol of appreciation for their outstanding contributions. We will also share key new 2024 initiatives with these top leaders.

In Conclusion:

Stemtech's re-entry into the Colombian market, planned product line expansion in Ecuador featuring StemFlo Advanced and MigraStem, the exciting pre-registration opportunity for IBPs, and the celebration of top producers underscore the company's commitment to international growth and the well-being of its community. These strategic initiatives position Stemtech strategically to capitalize on emerging opportunities, making 2024 a year of significant expansion and impact for the company.

ABOUT STEMTECH

Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (OTCQB:STEK) and has expanded business opportunities for its Independent Business Partners, who may earn incomes by sharing Stemtech products. January 2022 saw the introduction of new marketing efforts. In September 2022, the new Stemtech AdvanceOffice mobile app based on the VERB Technology platform was successfully launched as a powerful communication - recruiting tool for our Field On November 1, 2022, Stemtech introduced the new travel/sample size OraStem® Toothpaste. On December 6, Stemtech announced the promotion of Alejandro Carrillo to the role of Vice President Global Sales from his current role as Managing Director Latin Markets. Stemtech introduced the new CellectOne™ Rapid Renew Stem Cell Peptide Night Cream at their December 2022 International Leadership Event in Cancun, Mexico. January 10, 2023. Stemtech appoints Margie and Mike Mares to Field Advisory Board. Stemtech has Ranked Number 11 in Momentum out of 700+ top Global MLM companies by Business For Home independent MLM publication, January 23, 2023. Stemtech conducted Field Leadership Business Academies in Aguas Calientes, Mexico May 25 - 27, and in Las Vegas, NV on June 1 - 3. Stemtech rewards top Field Leaders with reward cruise in the South Caribbean December 9 - 16 2023 aboard the Royal Caribbean Rhapsody of the Seas.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on December 1, 2023. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

Investor Relations:

Gabriel Rodriguez
Email: erelationsgroup@gmail.com
Ph: 623-261-9046

Stemtech

Phone: 954-715-6000 ext 1040
Email: invrel@stemtech.com
www.Stemtech.com

SOURCE: Stemtech Corporation